Stopping Lymphedema Starts with PREVENT - Final 3-Year Primary Endpoint Results Published
Billr SP, DeKoven MP, Munakata J.

Economic Benefits of BIS-Aided Assessment of post-BC Lymphedema in the United States.

Economic analysis demonstrating that BIS utilization would lead to a cost savings which is magnified when considering sequelae of BCRL. Over 1 year, BIS-aided assessment of lymphedema for patients following treatment for BC results in cost savings, even without considering potential cost savings associated with averted downstream sequelae.
Open access: Yes